Related Experiment Video

Updated: Aug 29, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA

Steven R Lentz1, Roman N Rodionov, Sanjana Dayal

  • 1Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA. steven-lentz@uiowa.edu

Atherosclerosis. Supplements
|December 11, 2003
PubMed

Insights

High homocysteine levels (hyperhomocysteinemia) may harm blood vessels. This study explores how a substance called asymmetric dimethylarginine (ADMA) might contribute to this vascular damage, potentially impacting cardiovascular disease and stroke risk.

Area of Science:

  • Cardiovascular Science
  • Endothelial Function
  • Metabolic Disorders

Background:

  • Hyperhomocysteinemia is an emerging risk factor for cardiovascular disease and stroke.
  • Endothelial dysfunction, linked to nitric oxide deficiency, is a key feature of hyperhomocysteinemia.
  • Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and may play a role in this process.

Purpose of the Study:

  • To investigate the association between hyperhomocysteinemia and elevated levels of ADMA.
  • To explore the potential role of ADMA in the endothelial dysfunction observed in hyperhomocysteinemia.
  • To determine the mechanisms of ADMA accumulation in hyperhomocysteinemia and its in vivo significance.

Main Methods:

  • Review of existing literature on hyperhomocysteinemia, ADMA, and endothelial dysfunction.
  • Analysis of experimental models and human studies investigating plasma ADMA levels in hyperhomocysteinemia.
  • Exploration of potential molecular mechanisms linking hyperhomocysteinemia to ADMA accumulation.

Main Results:

  • Elevated plasma ADMA levels are consistently found in association with hyperhomocysteinemia.
  • ADMA's inhibition of nitric oxide synthase is a plausible mechanism for endothelial dysfunction in hyperhomocysteinemia.
  • Evidence suggests a link between hyperhomocysteinemia, increased ADMA, and impaired endothelial function in both animal and human studies.

Conclusions:

  • Asymmetric dimethylarginine (ADMA) is implicated in the endothelial dysfunction associated with hyperhomocysteinemia.
  • Further research is needed to elucidate the precise mechanisms of ADMA accumulation in hyperhomocysteinemia.
  • Understanding ADMA's role is crucial for defining its importance in the pathophysiology of hyperhomocysteinemia-related cardiovascular events.

More Related Videos

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly06:09

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...